CONCORD HC GP (02453) announced that as of May 2026, its subsidiary Guangzhou Concord Cancer Hospital's Proton Therapy Center has been operational for 18 months. The center has cumulatively served over 880 patients, with daily treatments surpassing 100 patients. This milestone signifies a new level of precision radiotherapy capability for cancer treatment in South China. Patient services have extended across 31 provincial-level administrative regions in China and over 20 countries worldwide, with patients ranging in age from 13 months to 91 years. The treatment scope covers various malignant tumors, including pediatric cancers, central nervous system tumors, head and neck cancers (such as nasopharyngeal carcinoma), thoracic cancers (such as lung cancer and esophageal cancer), breast cancer, abdominal cancers (such as liver cancer), urological cancers (such as prostate cancer), and soft tissue sarcomas. Moving forward, the company will continue to optimize service processes and enhance diagnostic and treatment efficiency, dedicated to providing high-quality, precise proton therapy services to more cancer patients.